Hepatocellular Carcinoma
Conditions
Brief summary
The purpose of this study is to observe and preliminary explore the efficacy and safety of combination of Apatinib and SHR-1210 regimen in treating advanced hepatocellular carcinoma.
Detailed description
SHR-1210 is a humanized monoclonal antibody against Programmed death 1(PD-1). Apatinib is a new kind of selective Vascular Endothelial Growth Factor Receptor 2(VEGFR-2) tyrosine kinase inhibitor (TKI). Patients with advanced HCC who failed or intolerable to sorafenib will receive apatinib 250mg orally every day and SHR-1210 200mg (3mg/kg for underweight patients) iv every 2 weeks. The efficacy and safety will be observed.
Interventions
DRUGSHR 1210+apatinib
SHR-1210 200mg (3mg/kg for underweight patients) iv every 2 weeks;Apatinib,250 mg/day.
Sponsors
Jiangsu HengRui Medicine Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Aged 18 years old, both genders. 2. Conform to the clinical diagnosis standard strictly or histological or cytological confirmation of HCC(hepatocellular carcinoma) and with at least one measurable lesion by computed tomography (CT) scan or magnetic resonance imaging (MRI) according to RECIST 1.1. 3. Liver function status Child-Pugh Class A. 4. Barcelona Clinic Liver Cancer stage Category B or C. 5. Failure or intolerance to prior treatment with targeted therapy. 6. Eastern Cooperative Oncology Group Performance Status of 0 or 1. 7. Life expectancy of at least 12 weeks. 8. Adequate bone marrow, liver and renal function (without blood transfusion, without growth factor or blood components support within 14 days before enrollment).
Exclusion criteria
1. Patients with any active autoimmune disease or history of autoimmune disease, including but not limited to the following: hepatitis, pneumonitis, uveitis, colitis (inflammatory bowel disease), hypophysitis, vasculitis, nephritis, hyperthyroidism, and hypothyroidism, except for subjects with vitiligo or resolved childhood asthma/atopy. Asthma that requires intermittent use of bronchodilators or other medical intervention should also be excluded. 2. Concurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic or absorbable topical corticosteroids. Doses \> 10 mg/day prednisone or equivalent are prohibited within 2 weeks before study drug administration. 3. More than one regimen. 4. Known history of hypersensitivity to any components of the SHR-1210 formulation, or other antibody formulation. 5. Known or occurrence of central nervous system (CNS) metastases or hepatic encephalopathy. 6. Patients with tumor burden ≥50% of the liver volume or received liver transplantation. 7. Patients with clinical symptoms of ascites. 8. Hypertension and unable to be controlled within normal level following treatment of anti-hypertension agents(within 3 months): systolic blood pressure \> 140 mmHg, diastolic blood pressure \> 90 mmHg. 9. Clinically significant cardiovascular and cerebrovascular diseases, including but not limited to severe acute myocardial infarction within 6 months before enrollment, unstable or severe angina, or coronary artery bypass surgery, Congestive heart failure (New York heart association (NYHA) class \> 2), ventricular arrhythmia which need medical intervention. 10. Coagulation abnormalities (INR\>2.0、PT\>16s), with bleeding tendency or are receiving thrombolytic or anticoagulant therapy. 11. Previous digestive tract bleeding history within 3 months or evident gastrointestinal bleeding tendency, such as: esophageal varices, local active ulcerative lesions, gastric ulcer and duodenal ulcer, the ulcerous colitis, gastrointestinal diseases such as portal hypertension or resection of tumor with bleeding risk, etc. 12. Previous Arterial/venous thrombosis events within 3 months. 13. Proteinuria ≥ (++) and 24 hours total urine protein \> 1.0 g. 14. Prior systemic chemotherapy, radiotherapy, immunotherapy, hormone therapy, surgery or target therapy within 4 weeks (Or 5 half-life of the drug, calculate the longer ) before the study drug administration, or any unresolved AEs \> Common Terminology Criteria for Adverse Events (CTCAE) Grade 1. 15. Active infection or an unexplained fever \> 38.5°C during screening visits or on the first scheduled day of dosing. 16. History of immunodeficiency or human immunodeficiency virus (HIV) infection. 17. HBV DNA\>2000 IU/ml（or 104copies/ml），HCV RNA\>103copies/ml，HBsAg+ and anti-HCV+； 18. Patients with other malignant tumor (except cured skin basal cell carcinoma and cervical carcinoma). 19. Patients who has bone metastasis, has received Palliative radiotherapy (radiotherapy area \> 5% marrow area). 20. Patients must not have had prior treatment with SHR-1210 or any other PD-L1 or PD-1 antagonists or apatinib. 21. Patients who may receive live vaccine during the study, or previous had vaccination within 4 weeks. 22. Any other medical, psychiatric, or social condition deemed by the investigator to be likely to interfere with a subject's rights, safety, welfare, or ability to sign informed consent, cooperate, and participate in the study or would interfere with the interpretation of the results.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate (ORR) | Up to approximately 12 months | Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of Response (DoR) | Up to approximately 12 months | Duration of Response (DoR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1). |
| Disease Control Rate (DCR) | Up to approximately 12 months | Disease Control Rate (DCR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1). |
| Time to Objective Response(TTR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1). | Up to approximately 12 months | Time to objective response，TTR |
| 9-month Survival Rate | Up to approximately 9 months | 9-month survival rate |
| 12-month Survival Rate | Up to approximately 12 months | 12-month survival rate |
| Overall Survival(OS) | Up to approximately 36 months | Overall survival(OS) |
| Progression-free Survival(PFS) | Up to approximately 12 months | Progression-free survival(PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1). |
Countries
China
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Continuous | 50.7 years STANDARD_DEVIATION 11 |
| Race and Ethnicity Not Collected | 0 Participants |
| Region of Enrollment China | 70 participants |
| Sex: Female, Male Female | 21 Participants |
| Sex: Female, Male Male | 106 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 118 / 190 |
| other Total, other adverse events | 189 / 190 |
| serious Total, serious adverse events | 92 / 190 |
Outcome results
None listed